ClinicalTrials.gg
CompletedNCT05403281Updated Jun 3, 2022

A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers

A Phase 1 interventional study of DW6012 in Healthy Subjects, sponsored by Dong Wha Pharmaceutical Co. Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-03.

Sponsored by Dong Wha Pharmaceutical Co. Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Nov 2021, registered May 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6012 and each component in healthy adult volunteers.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Dapagliflozin
  • Sitagliptin
  • sitagliptin phosphate
  • Dapagliflozin propanediol
03

In context

Lead sponsor

Dong Wha Pharmaceutical Co. Ltd. is the lead sponsor of 18 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects aged up to 19 years
  • Subjects weighing at least 50.0 kg and no more than 100 kg (inclusive) with a between 18.5 kg/m2 and 30.0 kg/m2
  • Subjects with neither congenital nor chronic diseases requiring treatment, and no abnormal symptoms or findings upon medical examination
  • Subjects considered eligible for the study participation in accordance to the results of clinical laboratory tests, vital signs, physical examinations and 12-lead conducted at the time of screening, based on the product (IP) characteristics
  • Subjects who has a full understanding in participation of the study, voluntarily provide a written consent in participation, and give full agreement in following the subject guidelines throughout the entire study period

Exclusion criteria

Exclusion Criteria:

  • Subjects with any hepatic, renal, nervous, respiratory, endocrine, circulatory, tumor, genitourinary, cardiovascular, digestive, musculoskeletal systemic diseases or other medical history
  • Subjects with genetic problems such as Lapp lactase deficiency (Lapp) or galactose intolerant galactose due to galactose intolerance
  • Subjects with a past medical history of gastrointestinal disease or gastrointestinal surgeries which may affect the absorption, distribution, metabolism and excretion of the IP
  • Pregnant subjects with a positive urine HCG test, or lactating female subjects
  • Subjects with reactions or a clinically significant medical history of hypersensitivity reactions to drug substances and additives containing drug substances or other drugs
  • Subjects with clinically significant 12-lead findings at the time of screening
  • Subjects with clinically significant laboratory test results as follows: Liver function test (, ALT, ALP, γ-GTP and total ), Creatinine,
  • Subjects with a past history of drug abuse or a positive urine drug test
  • Subjects with SBP ≥ 150 mmHg or ≤ 90 mmHg; DBP ≥ 100 mmHg or ≤ 60 mmHg; PR ≤ 40 bpm or ≥ 100 bpm at the time of screening
  • Subjects following an unusual diet or consumption of food which may affect the absorption, distribution, metabolism and excretion of the IP
  • Subjects who have administered any prescription drugs or herbal medicines that may affect the characteristics of clinical drugs within 2 weeks prior to the first administration date, or have administered any over-the-counter (OTC) or vitamin preparations within 10 days
  • Subjects taking drugs known to significantly induce or inhibit drug metabolizing enzymes, including barbitals within 1 months prior to the first IP administration
  • Subjects who have participated and were given any other study drugs in other clinical study within 6 months prior to the first IP administration
  • Subjects who have consistently drunk alcohol within 6 months
  • Subjects who have smoked more than 10 cigarettes/day on average
  • Subjects who have eaten or cannot refrain from eating grapefruit (grapefruit)-containing food from 48 hours before the first administration until the time of PSV
  • Subjects who have consumed or cannot refrain from consuming caffeine-containing food during the period from 24 hours prior to administration of each period to the time of the last blood sampling
  • Subjects who have done and are unable to refrain from strenuous activity
  • Subjects who are planning for pregnancy or not willing to use a medically reliable forms of
  • Subjects otherwise considered ineligible for participation due to other reasons including clinical laboratory test results not mentioned in the inclusion/exclusion criteria at the investigator's discretion
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Sequence A

    Period 1: Dapagliflozin and Sitagliptin / Period 2: DW6012

    Drug: DW6012

  • Experimental
    Sequence B

    Period 1: DW6012/ Period 2: Dapagliflozin and Sitagliptin

    Drug: DW6012

Interventions

  • DrugDW6012

    Drug pages: Dapagliflozin · Sitagliptin

    Drug: DW6012 Single oral administration of DW6012 after an overnight fast Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast

    Also known as: Dapagliflozin and Sitagliptin

06

What researchers measure

Primary outcomes

  1. AUC0-t of Dapagliflozin and Sitagliptin

    Time frame: up to 48 hours

  2. Cmax of Dapagliflozin and Sitagliptin

    Time frame: up to 48 hours

Secondary outcomes

  1. AUCinf

    Time frame: up to 48 hours

  2. Tmax

    Time frame: up to 48 hours

  3. t1/2

    Time frame: up to 48 hours

  4. CL/F

    Time frame: up to 48 hours

  5. Vd/F

    Time frame: up to 48 hours

  6. AUCextra

    Time frame: up to 48 hours

07

Study locations

1 site
  • Chungbuk National University Hospital
    Cheongju-si, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Dec 2021, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
Jun 3, 2022
StartActual
Nov 5, 2021
Primary completionActual
Dec 3, 2021
CompletionActual
Mar 28, 2022
Last update
Jun 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05403281
Lead sponsor
Dong Wha Pharmaceutical Co. Ltd.
Responsible party
Sponsor
First posted
Jun 3, 2022
Start date
Nov 5, 2021
Primary completion
Dec 3, 2021
Completion
Mar 28, 2022
Last update
Jun 3, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dapagliflozin · Sitagliptin

Start the discussion